In other experiments conducted with different T cell doses and initial tumor burdens (Supplementary Fig. 2a,b) we observed a similar trend, in that a proportion of mice bearing CD19+ PD-L1+ tumors either failed to clear tumors and succumbed to disease, or had delayed clearance/larger tumor burdens relative to animals with control CD19+ tumors. This evidence concerns the gene CD19 and neoplasm.